Shopping Cart
Remove All
Your shopping cart is currently empty
Tigatuzumab (Synonyms: TRA-8, TRA8, CS-1008, CS1008, Anti-Human TRAIL-R2 Recombinant Antibody)
Catalog No. T76793 Copy Product Info
🥰Excellent
Tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5 (DR5), is a TRAIL-R2 agonist with antitumor activity that induces apoptosis in cancer cells, and can be used to study pancreatic cancer.
Tigatuzumab
Copy Product Info🥰Excellent
Catalog No. T76793
Synonyms TRA-8, TRA8, CS-1008, CS1008, Anti-Human TRAIL-R2 Recombinant Antibody
Tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5 (DR5), is a TRAIL-R2 agonist with antitumor activity that induces apoptosis in cancer cells, and can be used to study pancreatic cancer.
Tigatuzumab
Cas No. 918127-53-4
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $228 | In Stock | In Stock | |
| 5 mg | $589 | In Stock | In Stock | |
| 10 mg | $993 | - | In Stock | |
| 25 mg | $1,470 | - | In Stock | |
| 50 mg | $1,980 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:98.9% (SDS-PAGE); 96.6% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5 (DR5), is a TRAIL-R2 agonist with antitumor activity that induces apoptosis in cancer cells, and can be used to study pancreatic cancer. |
| Targets&IC50 | MIAPaCa2 cells:2.95 μg/mL |
| In vitro | Tigatuzumab showed sensitivity to MIA PaCa-2 cells and BxPC-3 cells with IC50 values of 2.95 μg/mL and 8.21 μg/mL, respectively.[1] Tigatuzumab (3-8 μg/mL; 5 hours) was able to induce apoptosis in cancer cells. [1] |
| In vivo | Tigatuzumab (3 mg/kg; i.v.; once weekly for 4 weeks) was effective in inhibiting tumor growth of human pancreatic cancer MIA PaCa-2-RFP in a xenograft mouse model. [1] |
| Synonyms | TRA-8, TRA8, CS-1008, CS1008, Anti-Human TRAIL-R2 Recombinant Antibody |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | TNFRSF10B/TRAILR2/CD262 |
| Molecular Weight | 144.63 kDa |
| Cas No. | 918127-53-4 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Tigatuzumab | purchase Tigatuzumab | Tigatuzumab cost | order Tigatuzumab | Tigatuzumab in vivo | Tigatuzumab in vitro | Tigatuzumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.